Exploring the Role of Antidiabetic Medications in Lung Cancer Therapy: Clinical Insights and Potential Mechanisms

1

Lung cancer is the second most prevalent cancer globally and the leading cause of cancer-related deaths, highlighting a significant health concern.
2

Hypoglycemic agents, particularly metformin, show potential anti-tumor effects and may enhance the efficacy of traditional lung cancer therapies.
3

Diabetes mellitus contributes to a nutrient-rich environment for lung cancer cells, driving malignant proliferation and metastasis through various pathways.
4

Conventional glucose-lowering agents may influence cancer risk, with metformin potentially reducing this risk compared to insulin and sulfonylureas.
5

Understanding the mechanisms of hypoglycemic agents in lung cancer treatment is crucial for developing effective therapeutic strategies.

1